Current strategies to create tailored and risk-adapted therapies for CLL patients

Paula Cramer; Barbara Eichhorst; Hans Christian Reinhardt; Michael Hallek

doi:10.1016/j.beha.2016.08.010

Current strategies to create tailored and risk-adapted therapies for CLL patients

Best Pract Res Clin Haematol. 2016 Mar;29(1):111-121. doi: 10.1016/j.beha.2016.08.010. Epub 2016 Aug 12.

Authors

Paula Cramer¹, Barbara Eichhorst¹, Hans Christian Reinhardt², Michael Hallek³

Affiliations

¹ Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, University Hospital, Cologne, Germany; German CLL Study Group, University Hospital Cologne, Cologne, Germany.
² Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, University Hospital, Cologne, Germany; CECAD, University Hospital Cologne, Cologne Germany.
³ Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, University Hospital, Cologne, Germany; German CLL Study Group, University Hospital Cologne, Cologne, Germany; CECAD, University Hospital Cologne, Cologne Germany. Electronic address: Michael.hallek@uni-koeln.de.

PMID: 27742065
DOI: 10.1016/j.beha.2016.08.010

Abstract

Given the current dynamics in the development of novel agents for CLL therapy, the task to find optimal, non-toxic combinations has become the primary goal. This article gives an update of the most interesting novel drugs. The strategy of the German CLL Study Group to use these agents in combinations is described in detail, highlighting the strategy and first results of a recently started series of phase II combination trials, the BXX series using agents such as bendamustine, idelalisib, ibrutinib, obinutuzumab, ofatumumab and venetoclax.

Keywords: CLL; Ibrutinib; Idelalisib (CAL-101); MRD; Maintenance; Obinutuzumab (GA101); Ofatumumab; Venetoclax (ABT-199).

Publication types

Review

MeSH terms

Adenine / analogs & derivatives
Antibodies, Monoclonal / therapeutic use
Antibodies, Monoclonal, Humanized / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Bendamustine Hydrochloride / therapeutic use
Bridged Bicyclo Compounds, Heterocyclic / therapeutic use
Clinical Trials, Phase II as Topic
Humans
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
Piperidines
Precision Medicine / methods*
Precision Medicine / standards
Purines / therapeutic use
Pyrazoles / therapeutic use
Pyrimidines / therapeutic use
Quinazolinones / therapeutic use
Risk Factors
Sulfonamides / therapeutic use

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Bridged Bicyclo Compounds, Heterocyclic
Piperidines
Purines
Pyrazoles
Pyrimidines
Quinazolinones
Sulfonamides
ibrutinib
Bendamustine Hydrochloride
Adenine
ofatumumab
venetoclax
obinutuzumab
idelalisib